Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19672816rdf:typepubmed:Citationlld:pubmed
pubmed-article:19672816lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:19672816lifeskim:mentionsumls-concept:C0030095lld:lifeskim
pubmed-article:19672816lifeskim:mentionsumls-concept:C1705480lld:lifeskim
pubmed-article:19672816lifeskim:mentionsumls-concept:C0264716lld:lifeskim
pubmed-article:19672816lifeskim:mentionsumls-concept:C0017262lld:lifeskim
pubmed-article:19672816lifeskim:mentionsumls-concept:C1707455lld:lifeskim
pubmed-article:19672816lifeskim:mentionsumls-concept:C2911684lld:lifeskim
pubmed-article:19672816lifeskim:mentionsumls-concept:C0185117lld:lifeskim
pubmed-article:19672816pubmed:issue1lld:pubmed
pubmed-article:19672816pubmed:dateCreated2009-12-24lld:pubmed
pubmed-article:19672816pubmed:abstractTextThe hypothalamic nonapeptide vasopressin is a known player in the pathogenesis of chronic heart failure. According to the large body of clinical evidence, vasopressin has an impact on salt and water imbalance, hyponatremia, and subsequent renal insufficiency - the most common and destructive co-morbidity of patients afflicted with chronic heart failure. Despite the well-documented elevated levels of vasopressin in the blood of such patients, its expression in the magnocellular hypothalamic nuclei and transport to the posterior pituitary has not yet been investigated. In addition, the literature almost lacks the information on the contribution of another member of nonapeptide family, oxytocin, in the pathogenesis of this disease. Here we present a postmortem analysis of vasopressin and oxytocin-immunoreactive neurons and their terminals in the posterior pituitary of 8 male patients (53.8+/-9.3 years) who had died from CHF and 9 male controls (54.6+/-11.8 years). In line with previous clinical reports, our study on hypothalami of chronic heart failure patients revealed a significant increase in the relative profile density (+29%) of vasopressin-positive neurons in the hypothalamic supraoptic nucleus. Consistently we found a significant increase in the relative optic density of vasopressin-immunoreactivity in the posterior pituitary (+33%) of these patients. In contrast, the similar analysis applied for oxytocin neurons revealed no statistically significant differences to controls. In conclusion, our study provides the morphological evidence for activation of vasopressin (but not oxytocin) expression and vasopressin transport to the posterior pituitary in patients with chronic heart failure.lld:pubmed
pubmed-article:19672816pubmed:languageenglld:pubmed
pubmed-article:19672816pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19672816pubmed:citationSubsetIMlld:pubmed
pubmed-article:19672816pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19672816pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19672816pubmed:statusMEDLINElld:pubmed
pubmed-article:19672816pubmed:monthJanlld:pubmed
pubmed-article:19672816pubmed:issn1439-4286lld:pubmed
pubmed-article:19672816pubmed:authorpubmed-author:MorozovIu...lld:pubmed
pubmed-article:19672816pubmed:authorpubmed-author:JirikowskiG...lld:pubmed
pubmed-article:19672816pubmed:authorpubmed-author:DolzhikovA...lld:pubmed
pubmed-article:19672816pubmed:authorpubmed-author:GrinevichVVlld:pubmed
pubmed-article:19672816pubmed:authorpubmed-author:SivukhinaE...lld:pubmed
pubmed-article:19672816pubmed:copyrightInfoGeorg Thieme Verlag KG Stuttgart New York.lld:pubmed
pubmed-article:19672816pubmed:issnTypeElectroniclld:pubmed
pubmed-article:19672816pubmed:volume42lld:pubmed
pubmed-article:19672816pubmed:ownerNLMlld:pubmed
pubmed-article:19672816pubmed:authorsCompleteYlld:pubmed
pubmed-article:19672816pubmed:pagination56-60lld:pubmed
pubmed-article:19672816pubmed:meshHeadingpubmed-meshheading:19672816...lld:pubmed
pubmed-article:19672816pubmed:meshHeadingpubmed-meshheading:19672816...lld:pubmed
pubmed-article:19672816pubmed:meshHeadingpubmed-meshheading:19672816...lld:pubmed
pubmed-article:19672816pubmed:meshHeadingpubmed-meshheading:19672816...lld:pubmed
pubmed-article:19672816pubmed:meshHeadingpubmed-meshheading:19672816...lld:pubmed
pubmed-article:19672816pubmed:meshHeadingpubmed-meshheading:19672816...lld:pubmed
pubmed-article:19672816pubmed:meshHeadingpubmed-meshheading:19672816...lld:pubmed
pubmed-article:19672816pubmed:meshHeadingpubmed-meshheading:19672816...lld:pubmed
pubmed-article:19672816pubmed:meshHeadingpubmed-meshheading:19672816...lld:pubmed
pubmed-article:19672816pubmed:meshHeadingpubmed-meshheading:19672816...lld:pubmed
pubmed-article:19672816pubmed:year2010lld:pubmed
pubmed-article:19672816pubmed:articleTitleComparison of vasopressin and oxytocin expressions in the hypothalamo-neurohypophysial system of patients with chronic heart failure.lld:pubmed
pubmed-article:19672816pubmed:affiliationDepartment of Anatomy II, Friedrich-Schiller University, Jena, Germany.lld:pubmed
pubmed-article:19672816pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:19672816pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:19672816pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:551entrezgene:pubmedpubmed-article:19672816lld:entrezgene
entrez-gene:5020entrezgene:pubmedpubmed-article:19672816lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:19672816lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:19672816lld:entrezgene
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19672816lld:pubmed